Genezen Laboratories, a cell and gene therapy contract development and manufacturing organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master plan for a 75,000+ square foot cGMP-compliant Lentiviral vector production facility.   The first phase will see the construction of a 25,000 square feet site which will include a process development lab expansion, scheduled for completion in Autumn 2021. ...